In vitro antimicrobial susceptibility of Brucella species

MIC 50 and MIC 90 values of doxycycline, rifampicin, ciprofloxacin, trimethoprim-sulphamethoxazole and ceftriaxone for 42 blood isolates of Brucella species were determined using the Etest. Thirty-seven isolates were identified as B. melitensis and five as B. abortus. Doxycycline had the lowest and...

Full description

Saved in:
Bibliographic Details
Published in:International journal of antimicrobial agents 2004-04, Vol.23 (4), p.405-407
Main Authors: Baykam, Nurcan, Esener, Harika, Ergönül, Önder, Eren, Şebnem, Çeli̇kbas, Aysel K, Dokuzoǧuz, Başak
Format: Article
Language:English
Subjects:
Anti-Infective Agents - pharmacology
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Biological and medical sciences
Blood - microbiology
Brucella - drug effects
Brucella abortus
Brucella abortus - drug effects
Brucella melitensis
Brucella melitensis - drug effects
Brucella spp
Brucellosis - epidemiology
Brucellosis - microbiology
Drug Resistance, Bacterial
Endemic Diseases
Etest
Humans
Medical sciences
MIC
Microbial Sensitivity Tests - methods
Pharmacology. Drug treatments
Prospective Studies
Susceptibility
Turkey - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:MIC 50 and MIC 90 values of doxycycline, rifampicin, ciprofloxacin, trimethoprim-sulphamethoxazole and ceftriaxone for 42 blood isolates of Brucella species were determined using the Etest. Thirty-seven isolates were identified as B. melitensis and five as B. abortus. Doxycycline had the lowest and rifampicin the highest MIC 50 values. Four strains were non-susceptible to rifampicin, and one strain was resistant to trimethoprim-sulphamethoxazole. There is no significantly important resistance problem for antibiotics targeted against Brucella species in Turkey. However, since rifampicin is commonly used for prevalent diseases such as tuberculosis, the regional susceptibility pattern of rifampicin should be assessed periodically.
ISSN:0924-8579
1872-7913
DOI:10.1016/j.ijantimicag.2003.09.024